erytech
announces
abstract
results
eryaspase
phase
trial
acute
lymphoblastic
leukemia
selected
oral
presentation
american
society
hematology
annual
meeting
nasdaq
ery
oral
presentation
discuss
f
indings
nordic
society
paediatric
haematology
oncology
nopho
sponsored
phase
trial
confirm
potential
e
ryaspase
treatment
option
second
abstract
new
analysis
supporting
population
pharmacokinetics
eryaspase
patients
pancreatic
adenocarcinoma
also
presented
lyon
france
cambridge
mass
globe
newswire
erytech
pharma
nasdaq
euronext
eryp
biopharmaceutical
company
developing
innovative
therapies
encapsulating
therapeutic
drug
substances
inside
red
blood
cells
today
announces
abstract
detailing
results
nopho
sponsored
phase
trial
eryaspase
patients
selected
oral
presentation
upcoming
american
society
hematology
ash
annual
meeting
held
virtually
december
second
abstract
detailing
population
pharmacokinetics
eryaspase
pancreatic
adenocarcinoma
patients
accepted
poster
presentation
meeting
abstract
asparaginase
encapsulated
erythrocytes
eryaspase
promising
alternative
case
hypersensitivity
trial
evaluated
safety
pharmacological
profile
eryaspase
patients
developed
hypersensitivity
reactions
pegylated
asparaginase
trial
conducted
clinical
sites
nordic
baltic
countries
europe
enrolled
patients
study
findings
featured
oral
presentation
ash
line
stensig
lynggaard
representing
nopho
december
pst
est
cet
final
results
trial
presented
meeting
abstract
found
https
ash
webprogram
abstract
population
pharmacokinetics
eryaspase
patients
acute
lymphoblastic
leukemia
pancreatic
adenocarcinoma
analysis
population
pharmacokinetics
pop
pk
eryaspase
patients
pancreatic
adenocarcinoma
pac
presented
poster
frank
hoke
erytech
head
clinical
pharmacology
monday
december
pst
est
cet
analysis
shows
extended
circulation
time
eryaspase
provides
information
patient
factors
influence
exposure
eryaspase
evaluates
patient
population
pac
vs
formulation
native
vs
recombinant
abstract
found
https
ash
webprogram
proud
working
nopho
group
look
forward
presentation
new
clinical
data
treatment
ash
year
alongside
pop
pk
analysis
reporting
nopho
study
represents
significant
progress
towards
goal
finding
potential
path
forward
fda
eryaspase
said
iman
erytech
chief
medical
officer
believe
approach
development
eryaspase
provide
new
option
people
potentially
haematological
malignancies
solid
data
included
abstracts
based
data
second
quarter
final
oral
presentation
poster
include
additional
data
collected
abstract
submission
ash
congress
acute
lymphoblastic
leukemia
acute
lymphoblastic
leukemia
cancer
blood
bone
marrow
common
type
cancer
children
us
europe
cases
diagnosed
us
europe
year
majority
patients
diagnosed
age
asparaginase
integral
component
treatment
several
years
associated
hypersensitivity
patients
discontinuation
asparaginase
therapy
patients
associated
inferior
event
free
survival
highlighting
need
additional
asparaginase
based
treatment
options
erytech
eryaspase
erytech
biopharmaceutical
company
developing
innovative
red
blood
therapeutics
severe
forms
cancer
orphan
diseases
leveraging
proprietary
platform
uses
novel
technology
encapsulate
drug
substances
inside
red
blood
cells
erytech
developing
pipeline
product
candidates
patients
high
unmet
medical
needs
erytech
primary
focus
development
product
candidates
target
altered
metabolism
cancer
cells
depriving
amino
acids
necessary
growth
survival
company
lead
product
candidate
eryaspase
consists
encapsulated
inside
red
blood
cells
targets
cancer
cell
altered
asparagine
glutamine
metabolism
eryaspase
phase
clinical
development
treatment
pancreatic
cancer
phase
treatment
breast
cancer
phase
study
acute
lymphoblastic
leukemia
ongoing
nordic
countries
europe
erytech
produces
product
candidates
treatment
patients
europe
manufacturing
site
lyon
france
patients
united
states
gmp
manufacturing
site
princeton
new
jersey
usa
erytech
listed
nasdaq
global
select
market
united
states
ticker
eryp
euronext
regulated
market
paris
isin
code
ticker
eryp
erytech
part
cac
healthcare
cac
pharma
bio
cac
mid
small
cac
tradable
enternext
next
biotech
indexes
information
please
visit
information
press
release
contains
statements
including
limited
statements
respect
clinical
development
plans
eryaspase
potential
indications
benefits
eryaspase
statements
relating
clinical
trial
including
timeline
patient
enrollment
well
expected
timing
availability
results
interim
superiority
analysis
potential
impacts
company
clinical
trials
including
clinical
trial
due
coronavirus
pandemic
delays
regulatory
review
manufacturing
supply
chain
interruptions
overall
impact
pandemic
global
healthcare
system
well
company
business
financial
condition
results
operations
certain
statements
forecasts
estimates
recognized
use
words
without
limitation
believes
anticipates
expects
intends
plans
seeks
estimates
may
continue
similar
expressions
statements
forecasts
estimates
based
various
assumptions
assessments
known
unknown
risks
uncertainties
factors
deemed
reasonable
made
may
may
prove
correct
actual
events
difficult
predict
may
depend
upon
factors
beyond
erytech
control
guarantees
respect
pipeline
product
candidates
candidates
receive
necessary
regulatory
approvals
prove
commercially
successful
therefore
actual
results
timeline
may
turn
materially
different
anticipated
future
results
performance
achievements
expressed
implied
statements
forecasts
estimates
description
risks
uncertainties
risks
found
company
regulatory
filings
french
autorité
des
marchés
financiers
amf
company
securities
exchange
commission
sec
filings
reports
including
company
document
enregistrement
universel
filed
amf
march
company
annual
report
form
filed
sec
march
future
filings
reports
company
given
uncertainties
representations
made
accuracy
fairness
statements
forecasts
estimates
furthermore
statements
forecasts
estimates
speak
date
press
release
readers
cautioned
place
undue
reliance
statements
erytech
disclaims
obligation
update
statement
forecast
estimates
reflect
change
erytech
expectations
regard
thereto
change
events
conditions
circumstances
statement
forecast
estimate
based
except
extent
required
law
addition
pandemic
associated
containment
efforts
serious
adverse
impact
economy
severity
duration
uncertain
government
stabilization
efforts
partially
mitigate
consequences
extent
duration
impact
company
business
operations
highly
uncertain
impact
includes
effects
clinical
trial
operations
supply
chain
factors
influence
impact
company
business
operations
include
duration
extent
pandemic
extent
imposed
recommended
containment
mitigation
measures
general
economic
consequences
pandemic
pandemic
could
material
adverse
impact
company
business
operations
financial
results
extended
period
time
contacts
erytech
eric
soyer
cfo
coo
lifesci
advisors
llc
investor
relations
corey
davis
newcap
mathilde
bohin
delouvrier
investor
relations
nicolas
merigeau
media
relations
investors
cdavis
erytech
pdf
available
http
resource
download
